Drug Profile
Mometasone/formoterol - Merck & Co/Novartis
Alternative Names: Dulera; Formoterol/mometasone; MF/F; MFF 258; MK-0887A; MK-08887A; MK-887A; Mometasone furoate/formoterol fumarate; SCH 418131; ZenhaleLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis; Schering-Plough
- Developer Merck & Co; Novartis
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnadienediols; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
- No development reported Allergic asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 08 Mar 2022 Discontinued - Phase-III for Asthma (In children) in South Africa, Romania, Mexico, Guatemala, Denmark, Hungary, Latvia (Inhalation) (NDR Batch 21)
- 03 Feb 2020 No development reported - Phase-III for Asthma (In children) in Denmark (Inhalation)
- 03 Feb 2020 No development reported - Phase-III for Asthma (In children) in Guatemala (Inhalation)